industry news
From NCE to NICE: the role of Pharmacoeconomics What Is the Price Benchmark to Replace Average Wholesale Price (AWP)? NICE announces development of further Quality Standards Avastin patient access scheme too complicated, says NICE Comparative Effectiveness—of What? Evaluating Strategies to Improve Population Health Market access and patient access schemes Market access: Risk sharing and alternative pricing schemes US breast cancer drug decision 'marks start of death panels' Medical Affairs at the centre of life sciences innovation Rising Burden of Diseases Drives the Pharmaceutical Industry in East Africa Says Frost & Sullivan Is Health Care Special? CRD international register of ongoing systematic reviews Hospitals Should Plan Now for Value-Based Purchasing, Which May Be a Game-Changer Comparative Effectiveness Research Health care and revenue competition in Britain Literature Review Examines Value of Managed Care Pharmacy Tools Compelling Evidence Regarding Effectiveness Of Managed Care Pharmacy Tools In Achieving Intended Outcomes IBM, Aetna roll out cloud-based clinical decision support system Health Economics Spending Increases 45% in Emerging Markets, 8% in the US Health Secretary Andrew Lansley announces new NHS ‘quality standards’ PharmaNet, Abacus ally on ‘real world' research The Impact of Employer Health and Productivity Management Practices NICE ‘yes’ in 80% of treatment appraisals Providers Have Won Majority of RAC Claims Denials They Have Appealed Study examines UK’s NICE as model producer of HTA Health Secretary Andrew Lansley announces new NHS ‘quality standards’ Government kicks off consultation on outcomes framework Will More Insurers Control Health Care Costs Better? Will Janssen-Cilag's ADHD YouTube Video Go Viral and Win an Award? Reimbursement by Distributors Growing application of pharmacoeconomics and outcomes research in health-care decision-making in the Asia-Pacific region.Yang BM, Lee K. Value Health. 2009 Nov-Dec;12 Suppl 3:S1-2. Value-based Pricing to be Introduced to the UK Pharma Industry by 2014 Disclosing Industry Relationships — Toward an Improved Federal Research Policy Pharmacoeconomics: friend or foe? NHS reform – a bold vision or a dangerous gamble? GSK's Coverup of Avandia's Heart Risk Data: Is This How the Entire Industry Views Its Repsonsibility to Patients? Oncology drug price cuts announced in Italy related to perfomance based schemes US And European Prices Aren’t So Different After All Grand challenges in pharmacoeconomics and health outcomes White Paper: An Economic Assessment of the Relationship between Price Regulation and Incentives to Innovate in the Pharmaceutical Industry Clarifying Sources of Geographic Differences in Medicare Spending Is The Impact of Comparative Effectiveness Reports Being Evaluated? by Rebecca Singer Cohen Rebecca Singer Cohen View Author Bio and Bryan Luce Biosimilars’ Price Dynamic in Europe, Dr Matthias Liefner of Simon Kucher and Partners. AQoL Website - Centre for Health Economics, Monash University “How To Negotiate Salary”, a submitted article by Bill Cebak - Founder / Headhunter Global HEOR, Market Access and Medical Communications Practice since 1993 AMCP eDossier System: A Partnership that Works! AMCP News June 2010 Dartmouth Atlas: A Response to Its Researchers D2 Review : APHA and AMCP introduce MTM Connections a fantastic site for new professional opportunities Including Pregnant Women in Clinical Research Called ‘Imperative’ Selecting Quality and Resource Use Measures A Decision Guide for Community Quality Collaboratives Spending More on Drugs Doesn’t Mean Spending Less On Other Care Trendspotter: Consumer Survey Shows Opposition to Evidence-Based Medicine Patient Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Former CMS Official’s Off-Label Work May Help Reform Law’s CER Center Patient-reported outcome measures in the NHS: new methods for analysing and reporting EQ-5D data Integrated Health Ecosystem Key to Creating Better Health Outcomes and Managing Costs for Employers and Health Plans The Health Care Economy: New Questions About Costs, Quality And Care The Amazing Maze of US Health Care Universal Healthcare Myths | New Health Care Bill Facts Pricing, profits and pharmacoeconomics - for whose benefit? Symposium on Research Methods for Clinical and Comparative Effectiveness Studies – Part II France, Italy announce drug pricing cuts "AMCP Launches Health Care Reform Implementation Web Page" 2010 Lecture: US Health Care Reform Biosimilars: Issues Overview AZ's fixed-price deal on Iressa gets NICE nod Transforming Trial Results Into Practice Change: The Final Translational Hurdle Obama’s New Health Rationer-in-Chief NICE to move to value-based pricing? Reimbursement of New High Cost Drugs – Deal or No Deal! by:Michael Barry MD, PhD, FRCPI, 2009-2010 ISPOR President and Clinical Director National Centre for Pharmacoeconomics, St. James’s Hospital, Dublin, Ireland UK Government Wants To Revamp Drug Watch Dog NICE New FDA Campaign Targets Detailing, Trade Shows Advances in technology highlight need of Pharmacoeconomics in managing healthcare: Dr Rajesh Balakrishnan RFP for 2011 IBI/NBCH Health & Productivity Forum Funny Pharmacy Videos. These are Hysterical! Particularly "The PharmG's - Boom Intervention" Rap
about us
sponsored by
Become a sponsor How are we doing? Take our survey